Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osmetech starts clinical trials of new markers for warfarin test

This article was originally published in Clinica

Executive Summary

UK AIM-listed company Osmetech has started clinical trials for an extended version of its eSensor warfarin sensitivity test, which will incorporate additional biomarkers, including CYP450 4F2. The company, which also has US operations in Pasadena, California and Boston, exclusively licensed the marker from the Marshfield Clinic, Wisconsin, in November 2007. It expects to file for US FDA 510(k) clearance before the end of this year. Meanwhile, the company has launched its gene test for CYP450 2C9 (CYP2C9) drug metabolism. The gene is involved in the metabolism of 10% of all drugs, including warfarin and statins. It will be available for research use only on the eSensor XT-8 system. A recent evaluation of the eSensor XT-8 instrument, presented at the Association for Molecular Pathology meeting in Texas, found it has 100% accuracy and reproducibility.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel